A citation-based method for searching scientific literature

Helena Oliveres, Estela Pineda, Joan Maurel. Expert Opin Investig Drugs 2020
Times Cited: 10







List of co-cited articles
50 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Recent Progress in the Development of Small Molecule c-Met Inhibitors.
Peng-Cheng Lv, Yu-Shun Yang, Zhong-Chang Wang. Curr Top Med Chem 2019
13
30

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Gretchen M Schroeder, Yongmi An, Zhen-Wei Cai, Xiao-Tao Chen, Cheryl Clark, Lyndon A M Cornelius, Jun Dai, Johnni Gullo-Brown, Ashok Gupta, Benjamin Henley,[...]. J Med Chem 2009
219
20


RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.
Najme Faham, Alana L Welm. Cold Spring Harb Symp Quant Biol 2016
19
20

Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
István Szabadkai, Robert Torka, Rita Garamvölgyi, Ferenc Baska, Pál Gyulavári, Sándor Boros, Eszter Illyés, Axel Choidas, Axel Ullrich, László Őrfi. J Med Chem 2018
12
20


RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
Binbin Yin, Zhenping Liu, Yiyun Wang, Xuchu Wang, Weiwei Liu, Pan Yu, Xiuzhi Duan, Chunhua Liu, Yuhua Chen, Yurong Zhang,[...]. Oncol Rep 2017
18
20

Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Palak K Parikh, Manjunath D Ghate. Eur J Med Chem 2018
75
20

Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities.
Baohui Qi, Ying Yang, Huan He, Xupeng Yue, Yuting Zhou, Xing Zhou, Yuying Chen, Min Liu, Anmian Zhang, Fachang Wei. Eur J Med Chem 2018
20
20

Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.
Leonardo Pisani, Rosa Maria Iacobazzi, Marco Catto, Mariagrazia Rullo, Roberta Farina, Nunzio Denora, Saverio Cellamare, Cosimo Damiano Altomare. Eur J Med Chem 2019
26
20

Oncogenic signaling pathways activated by RON receptor tyrosine kinase.
Alla Danilkovitch-Miagkova. Curr Cancer Drug Targets 2003
54
20

Ron receptor tyrosine kinase signaling as a therapeutic target.
Nancy M Benight, Susan E Waltz. Expert Opin Ther Targets 2012
26
20

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Jieyi Wang, Liliane Goetsch, Lora Tucker, Qian Zhang, Alexandra Gonzalez, Kedar S Vaidya, Anatol Oleksijew, Erwin Boghaert, Minghao Song, Irina Sokolova,[...]. BMC Cancer 2016
42
20

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang,[...]. Cancer Res Treat 2020
10
20

The human met oncogene is related to the tyrosine kinase oncogenes.
M Dean, M Park, M M Le Beau, T S Robins, M O Diaz, J D Rowley, D G Blair, G F Vande Woude. Nature 1985
302
20

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang, Hang-Ping Yao. J Immunother Cancer 2019
11
20

Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.
Carolin Sellmann, Achim Doerner, Christine Knuehl, Nicolas Rasche, Vanita Sood, Simon Krah, Laura Rhiel, Annika Messemer, John Wesolowski, Mark Schuette,[...]. J Biol Chem 2016
37
20

Antibody-Drug Conjugates: A Comprehensive Review.
Puregmaa Khongorzul, Cai Jia Ling, Farhan Ullah Khan, Awais Ullah Ihsan, Juan Zhang. Mol Cancer Res 2020
175
20

MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
62
20

ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.
Jieyi Wang, Mark G Anderson, Anatol Oleksijew, Kedar S Vaidya, Erwin R Boghaert, Lora Tucker, Qian Zhang, Edward K Han, Joann P Palma, Louie Naumovski,[...]. Clin Cancer Res 2017
57
20

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Yu Jin Kim, Jong-Sun Choi, Jinwon Seo, Ji-Young Song, Seung Eun Lee, Mi Jung Kwon, Mi Jeong Kwon, Juthika Kundu, Kyungsoo Jung, Ensel Oh,[...]. Int J Cancer 2014
60
20

TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Marco Gymnopoulos, Oscar Betancourt, Vincent Blot, Ryo Fujita, Diana Galvan, Vincent Lieuw, Sophie Nguyen, Jeanette Snedden, Christine Stewart, Jose Villicana,[...]. Mol Oncol 2020
22
20

MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Jessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, Kristina Masson, Aaron Fulgham, Antoine Boudot, Tim Maiwald, Jeffrey D Kearns, Neeraj Kohli, Stephen Su,[...]. Proc Natl Acad Sci U S A 2019
17
20

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Sheri L Moores, Mark L Chiu, Barbara S Bushey, Kristen Chevalier, Leopoldo Luistro, Keri Dorn, Randall J Brezski, Peter Haytko, Thomas Kelly, Sheng-Jiun Wu,[...]. Cancer Res 2016
107
20


SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
Chang-Yong Yang, Lei Wang, Xing Sun, Mi Tang, Hai-Tian Quan, Lian-Shan Zhang, Li-Guang Lou, Shao-Hua Gou. Acta Pharmacol Sin 2019
22
20

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
Paolo M Comoglio, Livio Trusolino, Carla Boccaccio. Nat Rev Cancer 2018
156
20

Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Oshin Miranda, Mariya Farooqui, Jill M Siegfried. Cancers (Basel) 2018
37
20

Optimization techniques for novel c-Met kinase inhibitors.
Zhi-Gang Sun, Yong-An Yang, Zhi-Gang Zhang, Hai-Liang Zhu. Expert Opin Drug Discov 2019
14
20

c-Met targeting in advanced gastric cancer: An open challenge.
Luigi Marano, Rita Chiari, Alessio Fabozzi, Ferdinando De Vita, Virginia Boccardi, Giandomenico Roviello, Roberto Petrioli, Daniele Marrelli, Franco Roviello, Alberto Patriti. Cancer Lett 2015
49
20


Targeting the cancer kinome through polypharmacology.
Zachary A Knight, Henry Lin, Kevan M Shokat. Nat Rev Cancer 2010
497
20

Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, Maggie C U Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu,[...]. J Clin Oncol 2009
20

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.
Xing Huang, Enliang Li, Hang Shen, Xun Wang, Tianyu Tang, Xiaozhen Zhang, Jian Xu, Zengwei Tang, Chengxiang Guo, Xueli Bai,[...]. Front Cell Dev Biol 2020
23
20

Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ.
Patricia Casbas-Hernandez, Monica D'Arcy, Erick Roman-Perez, Heather Ann Brauer, Kirk McNaughton, Samantha M Miller, Raghav K Chhetri, Amy L Oldenburg, Jodie M Fleming, Keith D Amos,[...]. Breast Cancer Res 2013
32
20

Gene expression profiling of breast cell lines identifies potential new basal markers.
E Charafe-Jauffret, C Ginestier, F Monville, P Finetti, J Adélaïde, N Cervera, S Fekairi, L Xerri, J Jacquemier, D Birnbaum,[...]. Oncogene 2006
410
20

Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.
Jihong Ma, Marie C DeFrances, Chunbin Zou, Carla Johnson, Robert Ferrell, Reza Zarnegar. J Clin Invest 2009
37
20

Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.
Xixi Zhao, Jingkun Qu, Yuxin Hui, Hong Zhang, Yuchen Sun, Xu Liu, Xiaoyao Zhao, Zitong Zhao, Qian Yang, Feidi Wang,[...]. Oncotarget 2017
29
20

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
Melissa A Troester, Xuezheng Sun, Emma H Allott, Joseph Geradts, Stephanie M Cohen, Chiu-Kit Tse, Erin L Kirk, Leigh B Thorne, Michelle Mathews, Yan Li,[...]. J Natl Cancer Inst 2018
68
20

cMET and phospho-cMET protein levels in breast cancers and survival outcomes.
Kanwal P Raghav, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N Hortobagyi, Gordon B Mills, Funda Meric-Bernstam, George R Blumenschein, Ana M Gonzalez-Angulo. Clin Cancer Res 2012
86
20

Integrating access to care and tumor patterns by race and age in the Carolina Breast Cancer Study, 2008-2013.
Marc A Emerson, Yvonne M Golightly, Xianming Tan, Allison E Aiello, Katherine E Reeder-Hayes, Andrew F Olshan, H Shelton Earp, Melissa A Troester. Cancer Causes Control 2020
10
20

Normalization of RNA-seq data using factor analysis of control genes or samples.
Davide Risso, John Ngai, Terence P Speed, Sandrine Dudoit. Nat Biotechnol 2014
833
20

An approach for normalization and quality control for NanoString RNA expression data.
Arjun Bhattacharya, Alina M Hamilton, Helena Furberg, Eugene Pietzak, Mark P Purdue, Melissa A Troester, Katherine A Hoadley, Michael I Love. Brief Bioinform 2021
25
20


The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.
Rahul A Parikh, Peng Wang, Jan H Beumer, Edward Chu, Leonard J Appleman. Onco Targets Ther 2014
56
20

The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.
B Newman, P G Moorman, R Millikan, B F Qaqish, J Geradts, T E Aldrich, E T Liu. Breast Cancer Res Treat 1995
173
20

C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
Colan M Ho-Yen, Andrew R Green, Emad A Rakha, Adam R Brentnall, Ian O Ellis, Stephanie Kermorgant, J L Jones. Cancer 2014
35
20

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.
Benjamin Yaw Owusu, Robert Galemmo, James Janetka, Lidija Klampfer. Cancers (Basel) 2017
58
20

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
Carrie R Graveel, Jack D DeGroot, Yanli Su, Julie Koeman, Karl Dykema, Samuel Leung, Jacqueline Snider, Sherri R Davies, Pamela J Swiatek, Sandra Cottingham,[...]. Proc Natl Acad Sci U S A 2009
91
20

Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Paolo M Comoglio, Silvia Giordano, Livio Trusolino. Nat Rev Drug Discov 2008
650
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.